Provided by Tiger Trade Technology Pte. Ltd.

Passage Bio, Inc.

4.20
-0.2990-6.64%
Volume:26.48K
Turnover:118.96K
Market Cap:13.48M
PE:-0.37
High:4.73
Open:4.50
Low:4.20
Close:4.50
52wk High:20.00
52wk Low:3.29
Shares:3.21M
Float Shares:3.20M
Volume Ratio:1.51
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.3124
EPS(LYR):-14.3500
ROE:-169.09%
ROA:-45.62%
PB:3.02
PE(LYR):-0.29

Loading ...

Company Profile

Company Name:
Passage Bio, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
24
Office Location:
One Commerce Square,2005 Market Street,39th Floor,Philadelphia,Pennsylvania,United States
Zip Code:
19103
Fax:
- -
Introduction:
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Directors

Name
Position
Matthew R. Patterson
Chairman of the Board and Director
Peter G. Smith
Chief Executive Officer, Director and President
Linda C. Bain
Director
Maria Koehler
Director
Michael Landsittel
Director
Peter Colabuono
Director
Scott Biller
Director

Shareholders

Name
Position
Peter G. Smith
Chief Executive Officer, Director and President
Heather Wasserman
Chief Business Officer and Chief Operating Officer
Charles Michaud, Jr.
Interim Chief Financial Officer and Head of Finance
Dominic Reynolds
Chief Scientific Officer
Mythili Koneru
Chief Medical Officer
Nicole Sweeny
Chief Commercial Officer